Ophthalmology
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.
Diana V Do, Charles C Wykoff, Sobha Sivaprasad, David M Brown, David S Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Alyson J Berliner, Sergio Leal, Robert Vitti, Karen W Chu, Kimberly Reed
Published: 202510.1016/j.ophtha.2025.10.028
Abstract
PURPOSE: To follow up the previously published comparison of aflibercept 8 mg at extended dosing intervals versus aflibercept 2 mg every 8 weeks (2q8) in patients with diabetic macular edema (DME) through 48 weeks, we now report efficacy, durability,…
Preview only. Read the full abstract at the source